Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure: The Virginia - Anakinra Remodeling Trial 4
Patients who have a heart attack are at high risk for future development of heart failure ('weakening of the heart'). The researchers believe that the reaction of the heart muscle to injury (inflammation) during a heart attack may be contributing to the risk of heart failure. The current study will test the ability of an anti-inflammatory medicine (anakinra) to block the inflammation in the body during and after a heart attack.
∙ All criteria need to be met.
• Acute ST segment elevation myocardial infarction defined as:
‣ chest pain, consistent with angina, within the prior 12 hours (for intermittent pain lasting more than 12 hours, the time from the when the pain became severe and constant);
⁃ ST segment elevation on ECG \>1 mm in 2 or more anatomically contiguous leads;
⁃ Reperfusion strategy planned or completed (including percutaneous coronary intervention or fibrinolysis)
• Age \>21 years.